Table of Contents
London-based Zimbabwean billionaire Strive Masiyiwa has announced that a batch of COVID-19 vaccines recently shipped from South Africa to Europe will be returned. The announcement came on Sept. 2.
This follows a report that a shipment of Johnson and Johnson’s (J&J) COVID-19 vaccine to Europe was made by Aspen Pharmaceuticals, a South Africa-based pharmaceutical company.
Masiyiwa said the halting of the shipment was made possible due to the intervention of South African President Cyril Ramaphosa and EU Commission President Ursula von der Leyen.
The billionaire founder of Econet Group is a special envoy to the African Union for COVID-19 response. He coordinates Africa’s private-sector efforts to procure medical supplies to help fight the spread of COVID-19.
The agreement between Aspen and J&J involves the South African company importing the drug substance for the vaccine and packaging it in a “fill and finish” process in South Africa. However, J&J executes distribution.
According to the deal, J&J will supply South Africa with 31 million vaccine doses. Another contract shows that it will supply the African Union with 220 million doses, with a further 18- million option.
The agreement with South Africa was reached after J&J faced problems producing vaccines in the United States at a factory belonging to its partner, Emergent Biosolutions.
Although the European Commission was aware of the deal, it later described it as a temporary agreement after a series of backlash from the international community.
The EU’s response came after Director-General of the World Health Organization Tedros Adhanom Ghebreyesus said he was “stunned” to hear that J&J vaccines were being exported from South Africa to the EU, because the EU has very high vaccination rates, while even the most vulnerable in many African countries have not been vaccinated.
South African activists called for full disclosure of their government’s contracts with J&J and other vaccine manufacturers, threatening legal action to acquire the information.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
